Brighton Jones LLC decreased its position in Pfizer Inc. (NYSE:PFE) by 7.2% during the third quarter, Holdings Channel reports. The fund owned 39,047 shares of the biopharmaceutical company’s stock after selling 3,040 shares during the quarter. Brighton Jones LLC’s holdings in Pfizer were worth $1,394,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in the business. Peregrine Asset Advisers Inc. increased its stake in Pfizer by 0.5% in the 2nd quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 35 shares during the last quarter. Northwest Quadrant Wealth Management LLC increased its stake in Pfizer by 0.8% in the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 50 shares during the last quarter. River Wealth Advisors LLC increased its stake in Pfizer by 0.3% in the 2nd quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock worth $531,000 after acquiring an additional 55 shares during the last quarter. Stone House Investment Management LLC increased its stake in Pfizer by 1.0% in the 2nd quarter. Stone House Investment Management LLC now owns 7,236 shares of the biopharmaceutical company’s stock worth $243,000 after acquiring an additional 72 shares during the last quarter. Finally, Highland Private Wealth Management increased its position in shares of Pfizer by 0.8% during the 2nd quarter. Highland Private Wealth Management now owns 9,047 shares of the biopharmaceutical company’s stock valued at $304,000 after purchasing an additional 76 shares during the last quarter. 69.87% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Inc. (NYSE:PFE) opened at $34.67 on Tuesday. Pfizer Inc. has a 1-year low of $31.67 and a 1-year high of $39.43. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $206,660.00, a price-to-earnings ratio of 9.85, a P/E/G ratio of 2.20 and a beta of 0.94.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The company had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. During the same quarter in the previous year, the business earned $0.47 EPS. Pfizer’s revenue was up .6% compared to the same quarter last year. equities analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be issued a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 3.92%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Thursday, February 1st. Pfizer’s dividend payout ratio is currently 38.64%.
Pfizer announced that its Board of Directors has authorized a share repurchase program on Monday, December 18th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.
Several research firms have recently weighed in on PFE. BMO Capital Markets set a $39.00 target price on Pfizer and gave the company a “buy” rating in a research report on Tuesday, January 30th. SunTrust Banks reissued a “hold” rating and set a $40.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Monday, January 29th. Societe Generale set a $40.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Wednesday, January 31st. Morgan Stanley set a $43.00 target price on Pfizer and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, UBS Group set a $42.00 target price on Pfizer and gave the company a “buy” rating in a research report on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $39.25.
In other Pfizer news, insider Alexander R. Mackenzie sold 6,750 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the sale, the insider now directly owns 103,458 shares in the company, valued at approximately $3,827,946. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Rady A. Johnson sold 8,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the sale, the executive vice president now owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Brighton Jones LLC Trims Holdings in Pfizer Inc. (PFE)” was first published by Stock Observer and is the property of of Stock Observer. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.thestockobserver.com/2018/02/06/brighton-jones-llc-trims-holdings-in-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.